AI & ChatGPT searches , social queries for G1 THERAPEUTICS
Search references for G1 THERAPEUTICS. Phrases containing G1 THERAPEUTICS
See searches and references containing G1 THERAPEUTICS!
Search references for G1 THERAPEUTICS. Phrases containing G1 THERAPEUTICS
See searches and references containing G1 THERAPEUTICS!G1 THERAPEUTICS
Pharmaceutical company
G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing
G1_Therapeutics
German pharmaceutical company
cancer and lung cancer, for $1.5 billion. In June 2020, Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela), a CDK4/6
Boehringer_Ingelheim
British business executive (born 1964)
reasons" as chief executive officer of UnitedHealth Group in May 2025. G1 Therapeutics, non-executive director (since 2017) Synthego, member of the advisory
Andrew_Witty
Medication for HR+ HER2– breast cancer
seems to also have an inhibitory effect on Cyclin D3/CDK6 activity. G1 Therapeutics also has a CDK4/6 inhibitor, trilaciclib, which is up for FDA approval
Palbociclib
Chemical compound
breakthrough therapy designations. The FDA granted the approval of Cosela to G1 Therapeutics, Inc. "Cosela- trilaciclib injection, powder, lyophilized, for solution"
Trilaciclib
Chemical compound
degrader (SERD) discovered in Greg Thatcher's lab at UIC and developed by G1 Therapeutics for the treatment of estrogen receptor-positive (ER+) breast cancer
Rintodestrant
Market Front Row Motorsports Furnitureland South Fusion3 Fuzzy Logix G1 Therapeutics Geoff Bodine Racing Ginn Racing Glen Raven, Inc. Golden Corral Graco
List of companies of the United States by state
List_of_companies_of_the_United_States_by_state
Class of drugs
"Rintodestrant | oral selective estrogen receptor degrader (SERD) | G1 Therapeutics, Inc". www.g1therapeutics.com. Archived from the original on 2021-01-09
Selective estrogen receptor degrader
Selective_estrogen_receptor_degrader
Type of malignant cancer
Retrieved 2020-12-04. "Trilaciclib | intravenous CDK4/6 inhibitor | G1 Therapeutics, Inc". www.g1therapeutics.com. Retrieved 2020-12-28. Office of the
Small-cell_carcinoma
Any chemical that inhibits the function of CDKs
As of February 2017[update], trilaciclib (G1T28, CDK4/6 inhibitor, G1 Therapeutics) is in multiple phase II clinical trials. The drug is being tested
CDK_inhibitor
American cancer researcher (born 1966)
renew the body's various tissues. He is also one of the founders of G1 Therapeutics, listed $GTHX under the NASDAQ, which is a clinical-stage biopharmaceutical
Norman_Sharpless
Eli Lilly and Company/Loxo-Oncology - AdisInsight". "Rintodestrant - G1 Therapeutics - AdisInsight". Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q
List of investigational sex-hormonal agents
List_of_investigational_sex-hormonal_agents
Pharmaceuticals homozygous familial hypercholesterolemia Trilaciclib G1 Therapeutics myelosuppression, when administered prior to a platinum/etoposide or
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Medication
treatment of cutaneous squamous-cell carcinoma. It is a human immunoglobulin G1 (IgG1) programmed death ligand-1 (PD-L1) blocking antibody. The most common adverse
Cosibelimab
Cell signaling pathway
by ERK. The transition from G1 to S phase is coordinated by the activity of Cyclin D-Cdk4/6, which increases during late G1 phase as cells prepare to enter
MAPK/ERK_pathway
Experimental anti-cancer treatment
and Merck. It is an antibody–drug conjugate that consists of a humanized IgG1 monoclonal antibody against the tumor-associated antigen cadherin-6 (CDH6)
Raludotatug_deruxtecan
they were engaged in the production of human (as opposed to veterinary) therapeutics. Included here are companies engaged not only in pharmaceutical development
List of pharmaceutical companies
List_of_pharmaceutical_companies
Israeli pharmaceutical company
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food
Protalix_BioTherapeutics
Antibody against interleukin 6
remained unaffected. Ziltivekimab was initially developed by Corvidia Therapeutics and later acquired by Novo Nordisk, and is in phase 2 and 3 trials for
Ziltivekimab
Class of anticancer drugs
Hindi). "Our Pipeline | Jounce Therapeutics". Archived from the original on 2020-09-19. Retrieved 2020-09-19. Jounce Therapeutics, Inc. (2020-09-02). "Phase
PD-1_and_PD-L1_inhibitors
American biologist and pharmacologist
Heckmann, Bradlee Lawrence (2016). The function and regulation of the G0/G1 Switch Gene 2 (G0S2) (Thesis).[page needed][non-primary source needed] ORCID
Bradlee_Heckmann
Drug made from biological source
and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is
Biopharmaceutical
Quantitative measurement of the relative safety of a drug
imbalance of signals in the cell cycle. G1 and G2/M arrest were found to be major checkpoints by irradiating human cells. G1 arrest delays the repair mechanism
Therapeutic_index
Protein found in humans
complex including cyclin E or A. Cyclin E binds G1 phase Cdk2, which is required for the transition from G1 to S phase while binding with Cyclin A is required
Cyclin-dependent_kinase_2
Canadian biotechnology company
company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory
Zymeworks
American immunologist
industry. In the early 1990s, Springer founded LeukoSite to develop therapeutics based on leukocyte adhesion and trafficking biology. LeukoSite’s programs
Timothy_A._Springer
binding and inhibition of G1/S- and S-Cdks; however, they have also been shown to play an important role in activating the G1-CDKs CDK4 and CDK6. In addition
CIP/KIP
Medication
safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women". The Journal
Sotatercept
Form of immunotherapy
regions. Taking human gene sequences from the kappa light chain and the IgG1 heavy chain results in antibodies that are approximately 65% human. This reduces
Monoclonal_antibody_therapy
Monoclonal antibody
thyroid carcinoma (MTC). The parent antibody, labetuzumab, is a humanized IgG1 monoclonal antibody that selectively binds to carcinoembryonic antigen-related
Labetuzumab_govitecan
Cancer of the adrenal cortex
Parker KL, eds. (2006). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). McGraw-Hill. ISBN 978-0-07-142280-2. Terzolo M, Angeli A
Adrenocortical_carcinoma
Autoimmune disease resulting in skeletal muscle weakness
from triggering muscle contractions. Most cases are due to immunoglobulin G1 (IgG1) and IgG3 antibodies that attack AChR in the postsynaptic membrane, causing
Myasthenia_gravis
Unspecialized biological cell that can become specialized
importance of Cdk2 in G1 phase regulation by showing that G1 to S transition is delayed when Cdk2 activity is inhibited and G1 is arrest when Cdk2 is
Stem_cell
American pharmaceutical company
Vertex announced it would acquire Exonics Therapeutics for up to $1 billion and collaborate with CRISPR Therapeutics, boosting its development of treatments
Vertex_Pharmaceuticals
American chemist
integrates chemical biology and human biology to advance the science of therapeutics. Key advances include the discovery that small molecules can function
Stuart_Schreiber
fragment crystallizable region (Fc) and the hinge region of an immunoglobulin G1 (IgG1). Genetically modified cells produce SMIPs as antibody-like dimers, which
Small modular immunopharmaceutical
Small_modular_immunopharmaceutical
American scientist who co-discovered mTOR
School. Sabatini is the scientific founder of Navitor, Raze Therapeutics, and KSQ Therapeutics. In April 2021, after a new director of the Whitehead Institute
David_M._Sabatini
Mechanism of cell death
as a potential therapeutic target in cancers, and numerous approved therapeutics induce mitotic catastrophe. Multiple attempts to specifically define
Mitotic_catastrophe
murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this tumor, the P3K cells were isolated and developed
NS0_cell
American brain injury survivor (1823–1860)
ISBN 978-0-89862-200-3. Ebenezer, Ivor (2015). Neuropsychopharmacology and Therapeutics. John Wiley & Sons. p. 123. ISBN 978-1-118-38565-4. Bower, B. (May 21
Phineas_Gage
Enzyme that metabolizes substances by oxidation
enzyme activities, and impact of genetic variation". Pharmacology & Therapeutics. 138 (1): 103–41. doi:10.1016/j.pharmthera.2012.12.007. PMID 23333322
CYP3A4
American multinational biotechnology company
the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. Later in the same month, the company announced its
Biogen
Type of pluripotent blastocystic stem cell
GSK-3 inhibitor CHIR99021. ESCs divide very frequently due to a shortened G1 phase in their cell cycle. Rapid cell division allows the cells to quickly
Embryonic_stem_cell
Drug that inhibits activity of immune system
activity. In this way, it prevents the cell from transitioning from the G0 into G1 phase of the cell cycle. Tacrolimus is more potent than ciclosporin and has
Immunosuppressive_drug
Member of the cyclin family
member of the cyclin family. Cyclin E binds to G1 phase Cdk2, which is required for the transition from G1 to S phase of the cell cycle that determines
Cyclin_E
Type of endocrine gland cancer
Adenocarcinoma: Implications for Prevention and Treatment". Clinical Therapeutics. 38 (7): 1622–35. doi:10.1016/j.clinthera.2016.03.006. PMID 27041411
Pancreatic_cancer
Family of proteins
2008). "Small heat shock proteins in smooth muscle". Pharmacology & Therapeutics. 119 (1): 44–54. doi:10.1016/j.pharmthera.2008.04.005. PMC 2581864. PMID 18579210
Heat_shock_protein
Mammalian protein found in humans
mono-phosphorylated in early G1 cells, prior to hyper-phosphorylation after the restriction point in late G1. When a cell enters G1, Cyclin D- Cdk4/6 phosphorylates
Retinoblastoma_protein
Cell division into two identical cells
the process of cell division. Interphase is divided into three subphases: G1 (first gap), S (synthesis), and G2 (second gap). During all three parts of
Mitosis
Protein(s) forming a major part of an organism's immune system
models in studying antibodies. For example, mouse IgG1 is closer to human IgG2 than to human IgG1 in terms of its function. The term humoral immunity
Antibody
Cocktail of drugs ineffective in treating COVID-19
COVID kit. A significant milestone in this context was the Solidarity Therapeutics Trial, a platform coordinated by the WHO, which concluded that hydroxychloroquine
COVID_kit
cytotoxicity (ADCC) is increased. Most approved monoclonal antibodies are of the IgG1 isotype, where two N-linked biantennary complex-type oligosaccharides are
Afucosylated monoclonal antibodies
Afucosylated_monoclonal_antibodies
Mammalian protein found in humans
hepatic CYP2C9 and CYP2C19". The Journal of Pharmacology and Experimental Therapeutics. 308 (3): 965–974. doi:10.1124/jpet.103.060137. PMID 14634042. S2CID 14838446
CYP2C19
Chemical compound
interactions and metabolism of aflatoxin: an update". Pharmacology & Therapeutics. 65 (2): 163–192. doi:10.1016/0163-7258(94)00054-7. PMID 7540767. "Aflatoxin
Aflatoxin_B1
Egyptian-American medical researcher
inhibitor by Noda. Multiple CDK inhibitors have become approved as cancer therapeutics, including palbociclib, abemaciclib and ribociclib. In 2017, El-Deiry's
Wafik_El-Deiry
Compounds found in cannabis
glioma, liver, and breast cancer cell lines by triggering cell cycle arrest at G1 or S-Phase. In estrogen receptor-positive breast cancer models, CBN was found
Cannabinoid
Protein found in humans
diagnostic biomarkers and, eventually, potential development of new therapeutics. XRCC4 polymorphisms have been linked to a risk of susceptibility for
DNA_repair_protein_XRCC4
Monoclonal antibody
Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (TeGenero [de]), a spin-off of the University of Würzburg around immunologist
Theralizumab
American biotechnology company
studies. In January 2018, the company announced it would acquire Cascadian Therapeutics for $614 million. In September 2020, Merck & Co announced it would purchase
Seagen
Protein-coding gene in humans
cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. It is often referred to as a cell cycle inhibitor protein because its major
CDKN1B
Protein found in humans
catalytic subunit of the protein kinase complex, important for the G1 phase progression and G1/S transition of the cell cycle and the complex is composed also
Cyclin-dependent_kinase_6
Multipotent adult stem cells present in multiple tissues
[citation needed] The first clinical trials of MSCs were completed by Osiris Therapeutics, a pharmaceutical company co-founded in 1995 by Caplan, with entrepreneur
Mesenchymal_stem_cell
Protein-coding gene in the species Homo sapiens
are involved in cell cycle regulation. Cdc25C (G1/S positive regulator): Activation results in increased G1 → S Cdc25C (G2/M positive regulator): Activation
PIM1
Protein found in humans
D1 is a protein required for progression through the G1 phase of the cell cycle. During the G1 phase, it is synthesized rapidly and accumulates in the
Cyclin_D1
Human liver enzyme
Neonatal Opioid Toxicity from Breastfeeding". Clinical Pharmacology and Therapeutics. 108 (5): 964–970. doi:10.1002/cpt.1882. PMID 32378749. S2CID 218535295
CYP2D6
Investigational long COVID drugs
GPCRs) [11] RSLV-132 – fusion protein (RNase fused to the Fc domain of IgG1) [12] Sipavibart (AZD-3152; Kavigale) – monoclonal antibody against SARS-CoV-2
List of investigational long COVID drugs
List_of_investigational_long_COVID_drugs
Monoclonal antibody against IL-17
(2016). "Secukinumab for ankylosing spondylitis and psoriatic arthritis". Therapeutics and Clinical Risk Management. 12: 1587–1592. doi:10.2147/TCRM.S100091
Secukinumab
Damage in DNA which occurs naturally
three main checkpoints are at G1/s, G2/m, and at the spindle assembly checkpoint regulating progression through anaphase. G1 and G2 checkpoints involve scanning
DNA damage (naturally occurring)
DNA_damage_(naturally_occurring)
Chemical compound
accumulation of cyclin-dependent kinase inhibitors p21 and p27, and to subsequent G1-phase arrest, as seen in cells of different cancer lines. Compactin and lovastatin
Lovastatin
Oligonucleotides which recognize the exosites of human thrombin
have been widely studied and used for the development of aptamer-based therapeutics and diagnostics. The aptamer TBA (also known as G15D, HTQ, HD1, ARC183
Anti-thrombin_aptamers
Indian scientist and professor of cancer biology
Awarded for establishing the "Centre for Integrative Cancer Biology and Therapeutics," a Virtual Networked Centre in collaboration with Jawaharlal Nehru University
Rana_P_Singh
Cellular mechanism
cyclin-dependent kinase inhibitor p21 in apoptosis". Molecular Cancer Therapeutics. 1 (8): 639–49. PMID 12479224. Janion C (2001). "Some aspects of the
DNA_repair
Monoclonal antibody medication
E-mediated food allergy. Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody which specifically binds to free human immunoglobulin
Omalizumab
Mammalian protein found in Homo sapiens
maintain the current cell cycle step. There are two main checkpoints, the G1/S and the G2/M, during the cell cycle, which preserve correct progression
ATM_serine/threonine_kinase
Cancer medication
of a broad range of temozolomide-resistant gliomas". Molecular Cancer Therapeutics. 13 (8): 2004–2017. doi:10.1158/1535-7163.mct-13-0964. PMID 24994771
Temozolomide
Chemical changes in proteins following their translation from mRNA
"Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics". Chem Rev. 118 (3): 1216–1252. doi:10.1021/acs.chemrev.7b00181. PMC 6609103
Post-translational modification
Post-translational_modification
Species of yeast
prevention of antibiotic-associated diarrhoea". Alimentary Pharmacology & Therapeutics. 42 (7): 793–801. doi:10.1111/apt.13344. PMID 26216624. McFarland, Lynne
Saccharomyces_cerevisiae
July 2025. "Governments Spent at Least €93bn on COVID-19 Vaccines and Therapeutics During the Last 11 Months". BusinessWire. 11 January 2021. Retrieved
List_of_megaprojects
Antibodies from clones of the same blood cell
2018). "Inaugural Editorial: Searching for Magic Bullets". Antibody Therapeutics. 1 (1): 1–5. doi:10.1093/abt/tby001. PMC 6086361. PMID 30101214. Ho M
Monoclonal_antibody
BOINC based volunteer computing project researching protein folding
Phase 1 Human clinical trial in May 2021 with the support of Neoleukin Therapeutics, itself a spin-off from the IPD. Rosetta@home played a role in the development
Rosetta@home
Mammalian proteins found in humans
alternative splicing, called HLA-G1, HLA-G2,..., HLA-G7. The protein can be both membrane-bound and soluble. HLA-G1 through G4 are membrane bound and
HLA-G
Protein-coding gene in the species Homo sapiens
stimulation of phospholipase C". The Journal of Pharmacology and Experimental Therapeutics. 288 (1): 232–8. PMID 9862775. Dhawan BN, Cesselin F, Raghubir R, Reisine
Nociceptin_receptor
Protein created by joining other proteins into a single polypeptide
artificially by recombinant DNA technology for use in biological research or therapeutics. Chimeric or chimera usually designate hybrid proteins made of polypeptides
Fusion_protein
Form of milk produced immediately following the delivery of newborn
MA, Buchan G, Borissenko MV, Brooks HJ (2001). "A comparison of IgG and IgG1 activity in an early milk concentrate from non-immunised cows and a milk from
Colostrum
Class of drugs used to treat malignant tumors
; Lazo J. S. (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: The McGraw-Hill Companies Inc. pp. 1021–1404. ISBN 978-0071422802
Antineoplastic
Chemical compound
designations. The FDA granted the approval of Ogsiveo to SpringWorks Therapeutics Inc. Nirogacestat was granted breakthrough therapy designation by the
Nirogacestat
Enzyme protein
(June 2020). "PharmVar GeneFocus: CYP2C19". Clinical Pharmacology and Therapeutics. 109 (2): 352–366. doi:10.1002/cpt.1973. PMC 7769975. PMID 32602114.
CYP2C9
Species of snake
tolerance to crotoxin in mice". The Journal of Pharmacology and Experimental Therapeutics. 265 (1): 41–46. doi:10.1016/S0022-3565(25)38138-3. ISSN 0022-3565. PMID 8474024
Crotalus_durissus
Form of programmed cell death
2019). "Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics". Advanced Pharmaceutical Bulletin. 9 (2): 205–218. doi:10.15171/apb
Apoptosis
Protein-coding gene in the species Homo sapiens
and progression of cancer, and may serve as a novel target for cancer therapeutics. MAP4K4 is categorized under the mammalian sterile 20 protein (Ste20p)
MAP4K4
Class of enzymes
phosphorylates cyclins D and E, which are important for the transition from G1 to S phase, and causes their degradation. The transcription factors c-myc
GSK-3
Protein found in humans
developed by Ascentage Pharma. Lonitoclax is being developed by Lomond Therapeutics. Bcl-2 has been shown to interact with: BAK1, BCAP31, BCL2-like 1, BCL2L11
Bcl-2
Treatment of cancer using drugs that inhibit cell division or kill cells
chemotherapeutics, life-threatening effects can occur. Initially, the targeted therapeutics were supposed to be solely selective for one protein. Now it is clear
Chemotherapy
Set of three serine threonine-specific protein kinases
protein kinase B/Akt. implications for cancer therapy". Pharmacology & Therapeutics. 93 (2–3): 243–51. doi:10.1016/S0163-7258(02)00193-6. PMID 12191616.
Protein_kinase_B
Medical intervention
Docetaxel Treatment and Contributes to Increased Survival". Molecular Cancer Therapeutics. 2 (5): 479–488. PMID 12748310. Scagliotti, G (June 2006). "Proteasome
Treatment_of_lung_cancer
Group of pharmaceuticals that modulate the renin–angiotensin system
drug interactions in healthy volunteers". Clinical Pharmacology and Therapeutics. 72 (3): 238–246. doi:10.1067/mcp.2002.127945. ISSN 0009-9236. PMID 12235444
Angiotensin II receptor blocker
Angiotensin_II_receptor_blocker
Species of virus
"Adeno-associated virus vector integration". Current Opinion in Molecular Therapeutics. 11 (4): 442–7. PMC 2929125. PMID 19649989. Maguire AM, Simonelli F,
Adeno-associated_virus
medical source?] A 2006 study published in the Journal of Experimental Therapeutics and Oncology indicated that Colostrin reduces the mutation frequency
Colostrinin
Pharmaceutical drug
constant region for the heavy chain IgG1 and light chain kappa. The version of dinutuximab made by United Therapeutics, and marketed under the brand name
Dinutuximab
Mammalian protein found in Homo sapiens
Kuo TT, Aveson VG (2011-01-01). "Neonatal Fc receptor and IgG-based therapeutics". mAbs. 3 (5): 422–430. doi:10.4161/mabs.3.5.16983. PMC 3225846. PMID 22048693
Neonatal fragment crystallizable receptor
Neonatal_fragment_crystallizable_receptor
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS
G1 THERAPEUTICS